Literature DB >> 1396016

Blood pressure elevation versus abnormal albuminuria in the genesis and prediction of renal disease in diabetes.

C E Mogensen1, K W Hansen, R Osterby, E M Damsgaard.   

Abstract

A number of risk factors associated with the development of diabetic nephropathy has been described, such as elevated blood pressure, poor metabolic control, hyperlipidemia, and smoking. Abnormal albuminuria also is associated with progression of renal disease, but has until recently been considered principally a marker of disease activity rather than a risk factor. This article discusses the role of elevated blood pressure versus abnormal albuminuria in a genesis and prediction of renal disease in diabetes. Controversy exists regarding parental disposition to hypertension and early blood pressure elevation in the course of diabetes, but all studies agree that elevated blood pressure--in the presence of abnormal albuminuria--constitutes a risk factor. Because abnormal albuminuria is associated with progression disease, it may itself be a risk factor because increased macromolecular traffic over the glomerular membrane may produce glomerulopathy. Problems related to blood pressure measurement are important, and 24-h recordings of blood pressure may be recommended in some situations. Regarding renal structure, preliminary results suggest that structural lesions precede blood pressure elevation. The solid end point for evaluation of renal disease progression is the fall rate of GFR, with abnormal albuminuria as an intermediate end point, also in drug trials. Abnormal albuminuria may constitute a new indication for antihypertensive treatment, being, as it is, a clear indicator of organ damage, whereas elevated blood pressure with normal AER may not increase risk substantially.

Entities:  

Mesh:

Year:  1992        PMID: 1396016     DOI: 10.2337/diacare.15.9.1192

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  10 in total

1.  Diagnosis of an ectopic ureter in a girl by differential urine collection after administration of desmopressin acetate.

Authors:  A Thimm; M G Coulthard
Journal:  Arch Dis Child       Date:  2000-09       Impact factor: 3.791

2.  Effects of captopril treatment versus placebo on renal function in type 2 diabetic patients with microalbuminuria: a long-term study.

Authors:  M Capek; C Schnack; B Ludvik; A Kautzky-Willer; M Banyai; R Prager
Journal:  Clin Investig       Date:  1994-12

Review 3.  Report of the Canadian Hypertension Society Consensus Conference: 5. Hypertension and diabetes.

Authors:  K G Dawson; J K McKenzie; S A Ross; J L Chiasson; P Hamet
Journal:  CMAJ       Date:  1993-09-15       Impact factor: 8.262

4.  Acute renal effects of angiotensin converting enzyme inhibition in microalbuminuric type 1 diabetic patients.

Authors:  K W Hansen; M M Pedersen; J S Christiansen; C E Mogensen
Journal:  Acta Diabetol       Date:  1993       Impact factor: 4.280

5.  Prevalence of abnormal urinary albumin excretion in adolescents and children with insulin dependent diabetes: the MIDAC study. Microalbinuria in Diabetic Adolescents and Children (MIDAC) research group.

Authors:  T H Moore; J P Shield
Journal:  Arch Dis Child       Date:  2000-09       Impact factor: 3.791

6.  Development and progression of microalbuminuria in a clinic sample of patients with insulin dependent diabetes mellitus.

Authors:  C A Jones; G P Leese; S Kerr; K Bestwick; D I Isherwood; J P Vora; D A Hughes; C Smith
Journal:  Arch Dis Child       Date:  1998-06       Impact factor: 3.791

7.  Improvement of blood glucose control in IDDM patients retards the progression of morphological changes in early diabetic nephropathy.

Authors:  H J Bangstad; R Osterby; K Dahl-Jørgensen; K J Berg; A Hartmann; K F Hanssen
Journal:  Diabetologia       Date:  1994-05       Impact factor: 10.122

8.  Captopril and atenolol are equally effective in retarding progression of diabetic nephropathy. Results of a 2-year prospective, randomized study.

Authors:  L D Elving; J F Wetzels; H J van Lier; E de Nobel; J H Berden
Journal:  Diabetologia       Date:  1994-06       Impact factor: 10.122

9.  Blood pressure, retinopathy and urinary albumin excretion in IDDM: the EURODIAB IDDM Complications Study.

Authors:  J M Stephenson; J H Fuller; G C Viberti; A K Sjolie; R Navalesi
Journal:  Diabetologia       Date:  1995-05       Impact factor: 10.122

10.  Pitfalls in the measurement of the nocturnal blood pressure dip in adolescents with type 1 diabetes.

Authors:  Angela Delaney; Margaret Pellizzari; Phyllis W Speiser; Graeme R Frank
Journal:  Diabetes Care       Date:  2008-11-04       Impact factor: 17.152

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.